Receive valuable information about Vivaglobin®

If your question is about a medical condition, then you should consult with a healthcare professional or, in the case of an emergency, call 911 immediately.

Please contact us for additional information.

Yes, I would like to receive information about Vivaglobin^®, CSL Behring products, programs or services and join the Vivaglobin Voice™ program.

All fields marked with an asterisk (*) are required.

*Salutation:
*First Name:
*Last Name:
*I am a:
This is my:	Home Address Work Address
*Address 1
Address 2:
*City
*State
*ZIP Code:
Telephone Number
*E-mail Address:
*Confirm E-mail Address

If you would like to obtain additional information, please contact Consumer Affairs at 1-888-508-6978.

I would like to order a replacement Vivaglobin^® therapy journal.

I would like to receive a DVD about Vivaglobin^®, featuring a video on how to administer the product, physician testimonials, and information on living with PI.

If you have already been prescribed Vivaglobin^®, your DVD is included in the Patient Starter Kit that you may have received from your doctor.

I would like to receive a copy of the Vivaglobin^® Patient Brochure via postal mail.

If you have already been prescribed Vivaglobin^®, your Patient brochure is included in the Patient Starter Kit that you may have received from your doctor.

*Type in the verification word and click “Submit”:

Prior to submitting your information, please review our Privacy Policy.

Important Safety Information

Immune Globulin Subcutaneous (Human), Vivaglobin^®, is a prescription treatment for patients with primary immunodeficiency (PI).

Immune globulin products, such as Vivaglobin^®, should not be taken if you have a history of anaphylactic or severe systemic response to immune globulin (Ig) preparations. If you suspect you are having a severe reaction to Vivaglobin^®, discontinue treatment immediately and inform your doctor.

Vivaglobin^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical trials, the most frequent adverse event was mild or moderate swelling, redness, and itching at the injection site. Other adverse events included headache, gastrointestinal disorder, fever, nausea, sore throat, and rash. No serious reactions were observed, and reactions tended to decrease substantially with repeated use.

If you are receiving Ig therapy for the first time, are new to Vivaglobin^®, or have not received Ig therapy within the past eight weeks, your healthcare provider should monitor your initial treatment with Vivaglobin^®, as you could experience reactions including fever, chills, nausea, and vomiting. Rarely, these reactions may lead to shock.

Ig administration may impair the effectiveness of virus vaccines, such as measles, mumps and rubella. Consult your doctor if you plan to receive any vaccine.

In clinical studies, Vivaglobin^® has been shown to be safe and well tolerated in pediatric patients, without pediatric-specific dose requirements. Safety and effectiveness were not studied in subjects under 2 years of age.

Please see full Prescribing Information and Patient Product Information.